Evidence map›Paper›PMID 41276705›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026

Development and validation of a personalized web-based calculator of aggressive recurrence after surgery for early-stage hepatocellular carcinoma by machine learning.

Zi-Chen Yu, Kai Wang, Wen-Feng Lu, Zheng-Kang Fang, Kai-Di Wang, Yang Yu, Zi-Yang Bao, Zhe-Jin Shi, Jun-Wei Liu, Dong-Sheng Huang and 2 more

Abstract readValidation Study
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Zi-Chen YuGeneral Surgery, Cancer Center, Department of Hepatobiliary & Pancreatic Surgery and Minimally Invasive Surgery, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, 310014, Zhejiang, China.
Kai WangGeneral Surgery, Cancer Center, Department of Hepatobiliary & Pancreatic Surgery and Minimally Invasive Surgery, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, 310014, Zhejiang, China.
Wen-Feng LuDepartment of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (Navy Medical University), Shanghai, China.
Zheng-Kang FangGeneral Surgery, Cancer Center, Department of Hepatobiliary & Pancreatic Surgery and Minimally Invasive Surgery, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, 310014, Zhejiang, China.
Kai-Di WangGeneral Surgery, Cancer Center, Department of Hepatobiliary & Pancreatic Surgery and Minimally Invasive Surgery, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, 310014, Zhejiang, China.
Yang YuDepartment of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
Zi-Yang BaoGeneral Surgery, Cancer Center, Department of Hepatobiliary & Pancreatic Surgery and Minimally Invasive Surgery, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, 310014, Zhejiang, China.
Zhe-Jin ShiGeneral Surgery, Cancer Center, Department of Hepatobiliary & Pancreatic Surgery and Minimally Invasive Surgery, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, 310014, Zhejiang, China.
Jun-Wei LiuGeneral Surgery, Cancer Center, Department of Hepatobiliary & Pancreatic Surgery and Minimally Invasive Surgery, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, 310014, Zhejiang, China.
Dong-Sheng HuangGeneral Surgery, Cancer Center, Department of Hepatobiliary & Pancreatic Surgery and Minimally Invasive Surgery, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, 310014, Zhejiang, China.
Cheng-Wu ZhangGeneral Surgery, Cancer Center, Department of Hepatobiliary & Pancreatic Surgery and Minimally Invasive Surgery, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, 310014, Zhejiang, China.
Lei LiangGeneral Surgery, Cancer Center, Department of Hepatobiliary & Pancreatic Surgery and Minimally Invasive Surgery, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, 310014, Zhejiang, China. liangl1992@hotmail.com.ORCID http://orcid.org/0000-0003-3294-2978

Funding

Medicine and Health Science and Technology Project of Zhejiang Province No.2022KY532Medicine and Health Science and Technology Project of Zhejiang Province No.2024KY766National Natural Science Foundation of China No.82203403National Natural Science Foundation of China No. 82302915Zhejiang Provincial Natural Science Foundation of China No. LQ23H160049
6 · The paper itself

Abstract

backgroundAggressive recurrence (AR) is an important factor affecting prognosis after surgery for hepatocellular carcinoma (HCC). This study aimed to establish and evaluate a visual calculator to predict AR using by machine learning (ML) model.

methodsPatients diagnosed with HCC at an early stage were reviewed. The prediction ability of each model was evaluated using accuracy, sensitivity, specificity, precision, F1 score, and the area under the curve (AUC). Then, the model's prediction performance was evaluated by calibration curves, decision curve analysis (DCA), and precision-recall curves (PRC).

results483 patients were ultimately included in this study. The baseline characteristics indicate that patients in the AR group exhibit poorer liver function and more advanced tumor features. Then, nine risk features were identified and incorporated into the nine development models, respectively. Among the models, the XGBoost model showed the best prediction ability (AUC 0.986, 95% CI: 0.983-0.988). Calibration curves, DCA, and PRC further demonstrated the robust performance and clinical applicability. Then, A web-based calculator was built.

conclusionAn explainable XGBoost model to predict AR for patients with early-stage HCC after surgery was feasible and effective, suggesting its superior potential in tailoring surgical strategies and optimizing personalized postoperative treatment plans.

Indexed as

Carcinoma, HepatocellularInternetLiver NeoplasmsMachine LearningNeoplasm Recurrence, LocalAdultAgedFemaleHepatectomyHumansMaleMiddle AgedNeoplasm StagingPrognosisRetrospective StudiesRisk AssessmentAggressive recurrenceHepatocellular carcinomaMachine learningPrediction modelXGBoost

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.